PA8626501A1 - Nuevos derivados de bencil(ideno)-lactamas - Google Patents
Nuevos derivados de bencil(ideno)-lactamasInfo
- Publication number
- PA8626501A1 PA8626501A1 PA20058626501A PA8626501A PA8626501A1 PA 8626501 A1 PA8626501 A1 PA 8626501A1 PA 20058626501 A PA20058626501 A PA 20058626501A PA 8626501 A PA8626501 A PA 8626501A PA 8626501 A1 PA8626501 A1 PA 8626501A1
- Authority
- PA
- Panama
- Prior art keywords
- ideno
- bencil
- compounds
- lactamas
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A NUEVOS DERIVADOS DE BENCIL (IDENO)-LACTAMAS, COMPUESTOS DE FORMULA II EN LA QUE R1 ES UN GRUPO DE FORMULA G1 O G2 EXPUESTOS A CONTINUACION, EN DONDE R1,R3,R6,R13,X,A,N Y M SON COMO SE DEFINEN EN LA PRESENTE MEMORIA DESCRIPTIVA, SUS SALES FARMACEUTICAMENTE ACEPTABLES Y COMPOSICIONES FARMACEUTICAS QUE INCLUYEN ANTAGONISTAS SELECTIVOS, AGONISTAS INVERSOS Y AGONISTAS PARCIALES DE RECEPTORES (5-HT1) DE SEROTONINA 1, ESPECIFICAMENTE, DE UNO DE LOS RECEPTORES 5-HT1A Y 5-HT1B O DE AMBOS. LOS COMPUESTOS DE LA INVENCION SON UTILES PARA TRATAR O PREVENIR LA DEPRESION, ANSIEDAD, TRASTORNO OBSESIVO-COMPULSIVO (OCD) Y OTROS TRASTORNOS PARA LOS QUE ESTA INDICADO UN AGONISTA 5-HT1 Y TIENEN UNA CAPACIDAD POTENCIAL REDUCIDA DE EFECTOS SECUNDARIOS CARDIACOS, EN PARTICULAR PROLONGACION DE QTC.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55380804P | 2004-03-17 | 2004-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8626501A1 true PA8626501A1 (es) | 2005-11-25 |
Family
ID=34960867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20058626501A PA8626501A1 (es) | 2004-03-17 | 2005-03-17 | Nuevos derivados de bencil(ideno)-lactamas |
Country Status (29)
Country | Link |
---|---|
US (1) | US7479559B2 (es) |
EP (1) | EP1727794B1 (es) |
JP (1) | JP4880583B2 (es) |
KR (1) | KR20060124770A (es) |
CN (1) | CN1934081A (es) |
AP (1) | AP2006003726A0 (es) |
AR (1) | AR050403A1 (es) |
AT (1) | ATE533745T1 (es) |
AU (1) | AU2005223481A1 (es) |
BR (1) | BRPI0508825A (es) |
CA (1) | CA2559530C (es) |
CR (1) | CR8618A (es) |
DO (1) | DOP2005000035A (es) |
EA (1) | EA200601461A1 (es) |
EC (1) | ECSP066853A (es) |
ES (1) | ES2374629T3 (es) |
GT (1) | GT200500051A (es) |
IL (1) | IL178105A0 (es) |
MA (1) | MA28474B1 (es) |
NL (1) | NL1028558C2 (es) |
NO (1) | NO20063602L (es) |
PA (1) | PA8626501A1 (es) |
PE (1) | PE20051153A1 (es) |
SV (1) | SV2005002051A (es) |
TN (1) | TNSN06287A1 (es) |
TW (1) | TW200604165A (es) |
UY (1) | UY28811A1 (es) |
WO (1) | WO2005090300A1 (es) |
ZA (1) | ZA200607133B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006075226A1 (en) * | 2005-01-13 | 2006-07-20 | Pfizer Products Inc. | 11c-labeled benzyl-lactam compounds and their use as imaging agents |
CA2612268A1 (en) * | 2005-06-17 | 2006-12-28 | Pfizer Products Inc. | Metabolites of 1-[6-(1-ethyl-1-hydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one as seratonin receptor antagonists |
WO2007026219A2 (en) * | 2005-08-31 | 2007-03-08 | Pfizer Products Inc. | Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions |
WO2008068614A2 (en) * | 2006-12-06 | 2008-06-12 | Pfizer Products Inc. | Stereoselective synthesis of 1-[6-ethyl-1,2-dihydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one |
FR2948660B1 (fr) * | 2009-07-30 | 2011-08-19 | Oroxcell | Derives de 2-amino-2-phenyl-alkanol, leur preparation et les compositions pharmaceutiques qui les contiennent |
EP2338873A1 (en) | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
EP2515903A4 (en) * | 2009-12-23 | 2013-07-10 | Peter Maccallum Cancer Inst | COMPOUNDS, PREPARATION AND USES THEREOF |
AU2013302497A1 (en) | 2012-08-16 | 2015-03-05 | The Scripps Research Institute | Novel kappa opioid ligands |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
CA2935270A1 (en) | 2014-01-20 | 2015-07-23 | F. Hoffmann-La Roche Ag | N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders |
US10112929B2 (en) | 2015-03-09 | 2018-10-30 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58189163A (ja) * | 1982-04-02 | 1983-11-04 | Takeda Chem Ind Ltd | 縮合ピロリノン誘導体 |
CA2099233A1 (en) | 1992-06-29 | 1993-12-30 | Conrad P. Dorn | Morpholine and thiomorpholine tachykinin receptor antagonists |
ES2157256T3 (es) | 1993-03-16 | 2001-08-16 | Pfizer | Derivados de naftaleno. |
JP3786983B2 (ja) * | 1994-01-27 | 2006-06-21 | シエーリング アクチエンゲゼルシャフト | ピロリジノン誘導体 |
GB9410512D0 (en) | 1994-05-25 | 1994-07-13 | Smithkline Beecham Plc | Novel treatment |
DK0767782T3 (da) | 1994-06-29 | 2002-02-18 | Pfizer | Aryl- og heteroarylalkoxynaphthalenderivater |
EP0894085B1 (en) * | 1996-03-29 | 2005-08-17 | Pfizer Inc. | Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors |
UA56185C2 (uk) * | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
US6423708B1 (en) * | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
DE10002509A1 (de) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
US20020049211A1 (en) * | 2000-09-06 | 2002-04-25 | Sobolov-Jaynes Susan Beth | Combination treatment for depression and anxiety |
TWI263640B (en) * | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
-
2005
- 2005-03-07 WO PCT/IB2005/000583 patent/WO2005090300A1/en active Application Filing
- 2005-03-07 KR KR1020067019078A patent/KR20060124770A/ko not_active Application Discontinuation
- 2005-03-07 ES ES05708687T patent/ES2374629T3/es active Active
- 2005-03-07 EP EP05708687A patent/EP1727794B1/en active Active
- 2005-03-07 JP JP2007503427A patent/JP4880583B2/ja not_active Expired - Fee Related
- 2005-03-07 CA CA2559530A patent/CA2559530C/en not_active Expired - Fee Related
- 2005-03-07 AT AT05708687T patent/ATE533745T1/de active
- 2005-03-07 BR BRPI0508825-9A patent/BRPI0508825A/pt not_active IP Right Cessation
- 2005-03-07 CN CNA2005800085634A patent/CN1934081A/zh active Pending
- 2005-03-07 AU AU2005223481A patent/AU2005223481A1/en not_active Abandoned
- 2005-03-07 EA EA200601461A patent/EA200601461A1/ru unknown
- 2005-03-07 AP AP2006003726A patent/AP2006003726A0/xx unknown
- 2005-03-10 DO DO2005000035A patent/DOP2005000035A/es unknown
- 2005-03-15 GT GT200500051A patent/GT200500051A/es unknown
- 2005-03-15 UY UY28811A patent/UY28811A1/es not_active Application Discontinuation
- 2005-03-15 TW TW094107893A patent/TW200604165A/zh unknown
- 2005-03-15 PE PE2005000296A patent/PE20051153A1/es not_active Application Discontinuation
- 2005-03-16 AR ARP050101025A patent/AR050403A1/es unknown
- 2005-03-16 SV SV2005002051A patent/SV2005002051A/es not_active Application Discontinuation
- 2005-03-16 NL NL1028558A patent/NL1028558C2/nl not_active IP Right Cessation
- 2005-03-17 PA PA20058626501A patent/PA8626501A1/es unknown
- 2005-03-17 US US11/083,188 patent/US7479559B2/en not_active Expired - Fee Related
-
2006
- 2006-08-09 NO NO20063602A patent/NO20063602L/no not_active Application Discontinuation
- 2006-08-25 ZA ZA200607133A patent/ZA200607133B/en unknown
- 2006-09-13 CR CR8618A patent/CR8618A/es not_active Application Discontinuation
- 2006-09-14 IL IL178105A patent/IL178105A0/en unknown
- 2006-09-15 TN TNP2006000287A patent/TNSN06287A1/fr unknown
- 2006-09-15 EC EC2006006853A patent/ECSP066853A/es unknown
- 2006-09-15 MA MA29327A patent/MA28474B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AP2006003726A0 (en) | 2006-10-31 |
TNSN06287A1 (fr) | 2007-12-03 |
ATE533745T1 (de) | 2011-12-15 |
ZA200607133B (en) | 2007-12-27 |
AR050403A1 (es) | 2006-10-25 |
MA28474B1 (fr) | 2007-03-01 |
EA200601461A1 (ru) | 2007-02-27 |
JP4880583B2 (ja) | 2012-02-22 |
BRPI0508825A (pt) | 2007-08-14 |
EP1727794B1 (en) | 2011-11-16 |
CN1934081A (zh) | 2007-03-21 |
KR20060124770A (ko) | 2006-12-05 |
NO20063602L (no) | 2006-09-08 |
ECSP066853A (es) | 2006-11-24 |
NL1028558A1 (nl) | 2005-09-20 |
SV2005002051A (es) | 2005-12-13 |
AU2005223481A1 (en) | 2005-09-29 |
NL1028558C2 (nl) | 2006-06-27 |
JP2007529495A (ja) | 2007-10-25 |
GT200500051A (es) | 2005-10-24 |
US20050245521A1 (en) | 2005-11-03 |
US7479559B2 (en) | 2009-01-20 |
UY28811A1 (es) | 2005-10-31 |
CA2559530C (en) | 2012-04-24 |
CR8618A (es) | 2006-11-15 |
CA2559530A1 (en) | 2005-09-29 |
TW200604165A (en) | 2006-02-01 |
EP1727794A1 (en) | 2006-12-06 |
ES2374629T3 (es) | 2012-02-20 |
PE20051153A1 (es) | 2006-01-28 |
WO2005090300A1 (en) | 2005-09-29 |
IL178105A0 (en) | 2006-12-31 |
DOP2005000035A (es) | 2005-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8626501A1 (es) | Nuevos derivados de bencil(ideno)-lactamas | |
GT200500309A (es) | Derivados de sulfonilbencilimidazol | |
ECSP066520A (es) | Derivados de dihidrobenzofuranilo alcanamina y métodos para su uso | |
UY28765A1 (es) | Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico | |
NI201000059A (es) | Inhibidores de la cinasa c-fms. | |
DK1723144T3 (da) | Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister | |
NO20070532L (no) | Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer | |
PA8845601A1 (es) | Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1) | |
DE602004021921D1 (de) | Azabicycloalkanverbindungen als muscarinrezeptor antagonisten | |
ATE463495T1 (de) | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten | |
BRPI0910182A2 (pt) | composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto" | |
DK1807434T3 (da) | Thienopyridiner som allosteriske potentiatorer af M4- muscarinreceptoren | |
CL2004000918A1 (es) | Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria | |
EA200700365A1 (ru) | Производные индол-2-карбоксамидина как антагонисты nmda рецептора | |
DE602005027870D1 (de) | Cgrp-rezeptorantagonisten | |
PE20010989A1 (es) | 8-arilquinolinas sustituidas inhibidoras de 4-fosfodiesterasa | |
MX2007004661A (es) | Derivados de 1-(hetero)aril-3-amino-pirrolidina para usarse como antagonistas del receptor mglur3. | |
AR046756A1 (es) | Derivados de hidronopol como agonistas de receptores orl-1 humanos. | |
BRPI0414643A (pt) | composto, composições farmacêuticas, e, uso de um composto | |
DK1861360T3 (da) | Pyrrolidin-derivater som histamin-H3-receptorantagonister | |
UY29733A1 (es) | Piperazinas acetilenicas como antagonistas de receptores de glutamato metabotrópicos | |
CL2009001146A1 (es) | Compuestos derivados de 5-(5-(2-(3,5-bis(trifluorometil)fenil)-n,2-dimetilpropanoamida)-4-(4-fluoro-2-metilfenil)piridin-2-il)pirrolidin-2-carboxamida, antagonistas de los receptores nk-1; composicion farmaceutica; y uso del compuesto para el tratamiento de la depresion; ansiedad, trastornos del sueño o emesis. | |
PE20090513A1 (es) | Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3 | |
PE20081495A1 (es) | Derivados 4,5-difenilpirrol-2-carboxamida como antagonistas de los receptores cb1 | |
WO2005113535A3 (en) | Pyrazinylmethyl lactam derivatives |